Mereo BioPharma Group plc
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-7.0M | $-6.7M | $-7.4M | $-7.0M | $-14.6M | $-12.9M | $-7.0M | $-15.0M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $38.0K | $44.0K | $36.0K | $39.0K | $44.0K | $38.0K | $-98.0K | $100.0K |
| Amortization | $127.0K | $127.0K | $424.0K | $-183.0K | $118.0K | $106.0K | $110.0K | $112.0K |
| Stock-Based Compensation | $1.3M | $1.6M | $1.5M | $1.7M | $2.1M | $2.3M | $1.5M | $1.7M |
| Net Cash from Operating Activities | $-6.0M | $-4.3M | $-7.7M | $-7.3M | $-7.7M | $-8.3M | $-9.4M | $-7.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | $0 | $20.0K | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-300.0K | $0 | $300.0K | $0 | $-320.0K | $0 | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $0 | $0 | $39.0K | $0 | $-134.0K | $422.0K | $-40.0K | $-594.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-6.0M | $-4.3M | $-7.7M | $-7.3M | $-7.7M | $-8.3M | $-9.4M | $-7.5M |